View this email in your browser
Share Share
Tweet Tweet
Forward Forward


Bringing you our latest news, features and guidance.
March 2021
COVID-19NewsInto practice  | Get involved | Events 


New single guideline for managing COVID-19 in children and adults

Our new guideline brings together existing recommendations on managing COVID-19 in children, young people and adults in all care settings. It includes new recommendations on therapeutics and replaces our COVID-19 rapid guidelines on:

  • critical care in adults
  • managing symptoms (including at the end of life) in the community
  • managing suspected or confirmed pneumonia in adults in the community
  • acute myocardial injury
  • antibiotics for pneumonia in adults in hospital
  • acute kidney injury in hospital
  • reducing the risk of venous thromboembolism in over 16s with COVID-19.
View all our COVID-19 guidance


Man in a wheelchair and carer supporting him
GP and child having a chat with Covid masks on

New quality standard on improving the wellbeing of unpaid carers

Our quality standard sets out the need for practitioners to identify adults who are unpaid carers of people over 16 years old, and direct them to available advice and support. We also advise employers to provide supportive working arrangements for carers. This might include flexible hours or providing a private space to take personal phone calls, as well as other initiatives that support mental wellbeing.

Children and young people need accurate, accessible information about their healthcare

Our new draft guideline recommends ensuring children and young people are fully informed about their health, so that they are empowered to take an active role in their care. It emphasises the need to provide children and young people with clear and accurate information that can be tailored to each individual patient’s level of maturity and understanding.

The Zolgensma drug ampules and box

Life-changing gene therapy for treating spinal muscular atrophy approved

A new and potentially curative one-off gene therapy for babies with the rare genetic disorder spinal muscular atrophy (SMA) is set to become the most expensive treatment ever approved by NICE. The approval reflects the exceptional benefit this treatment can offer young babies, potentially allowing them to reach normal childhood developmental milestones. 

Clarification on use of our cannabis-based medicinal products guideline

Our recent clarification relates to the use of cannabis-based medicinal products to treat severe treatment-resistant epilepsy in children. The clarification makes clear that patients in this population can be prescribed cannabis-based medicinal products if the healthcare professional considers that that would be appropriate on a balance of benefit and risk, and in consultation with the patient, and their families and carers or guardian.

Catch up on all our latest news articles
NICE Talks podcast logo

NICE process review: should you take part?

In our monthly podcast we've asked Eric Low, of Eric Low Consulting and former chief executive of Myeloma UK and Jennifer Prescott, programme director in the Centre for Health Technology Evaluation at NICE, why everyone with an interest in NICE should take part in our process review consultation.

Master’s degree in evaluation of healthcare interventions and outcomes

Applications are now open for the November 2021 intake of this joint LSE and NICE master’s programme. NICE’s involvement provides a unique opportunity to understand health technology assessment from an insider’s perspective. Our expert speakers will provide part of the core teaching. This will include a pragmatic exploration of the challenges our committees face during the decision-making process.

The MSc, which takes 2 years to complete part-time, is well-suited to those from a range of professional backgrounds, from the pharmaceutical industry to medical and academia. The course schedule allows participants to complete the degree alongside full-time work.
Learn more about LSE-NICE MSc

Into practice

Join our audience insight community

We’re looking for new members from the health and social care sector.  Join over 1,500 healthcare, social care and public health professionals , to help inform and develop our work. You’ll be invited to share your views on topics such as:

  • our guidance and rapid guidance
  • implementing our guidance and views on our support and resources
  • usability of our website and other resources
  • our strategic projects.

Should you decide to join us, you’ll have the flexibility of participating in a way that suits your existing commitments, including:

  • focus groups and workshops
  • in-depth interviews
  • user testing
  • surveys.
Join our audience insight community
Picture montage with the faces of our six new non-executive directors

6 new non-executive directors appointed to our board

Our new non-executive directors will bring an impressive array of expertise in guiding NICE to deliver our objectives and implementation of our new strategic plan.

Get involved

Have your say: public consultation on our health technology evaluation processes

Our public consultation on proposals for changes to the processes NICE uses to produce its guidance on medicines, medical devices, diagnostics and digital health technologies is open until Thursday 15 April 2021.

Get involved in the consultation

Comment on a consultation

Our current consultations include:

Consultation is a key part of our guidance development process. It enables those with an interest in our guidance to comment at specific stages and feedback into the decision-making process.
See all our open consultations

Join a committee

We have a number of current vacancies for health and social care professionals, and lay people, to join our committees. Topics include multiple sclerosis, lung cancer and weight management. Join and have an active role in producing a guideline or quality standard.

See our current committee vacancies

Observe a meeting

Due to the coronavirus pandemic, we're currently holding all our public meetings virtually. You'll need to register in advance to join. 

Upcoming public meeting:

  • Friday 23 April 2021 – Medical technologies advisory committee.
    • Evaluation of GID-MT550 DyeVert for reducing contrast media in coronary and peripheral angiography.
    • Evaluation of GID-MT551 Prontosan for acute and chronic wounds
    Registration closes Tuesday 6 April 2021.
    Agenda and register here
Our advisory committee meetings, technology appraisal appeal hearings and public board meetings are open to the public. Holding them in public supports our commitment to having processes in place that are rigorous, open, and transparent.
See all our public meetings


Generic graphic with the details of the launch strategy event

NICE to launch new 5-year strategy

Join us for the virtual launch of our ambitious 5-year strategy and learn what it means for the health and care sector on Monday 19 April 2021, 11am to 12:15pm.

Hear directly from our leadership team and board about how we plan to make our guidance easier to access and use, and become more dynamic and responsive in our vital work to improve health and care outcomes.

Register to attend strategy launch
Branded generic graphic with the details of the HTAi 2021 virtual meeting

HTAi 2021 virtual annual meeting

Health Technology Assessment international’s (HTAi) annual meeting will take place online:

  • Saturday 19 to Wednesday 23 June 2021.

Registration is now open and the speakers for HTAi 2021 have also been announced.

You’ll find details on the plenary sessions, workshops and presentations on the HTAi 2021 virtual annual meeting website.

Register to attend HTAi 2021

unsubscribe from this list